An Open-label, First-in-Human, Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-61610588, a Fully Human IgG1 Kappa Anti-VISTA (V-domain Ig Suppressor of T-cell Activation) Monoclonal Antibody, in Subjects With Advanced Cancer
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Enrollment
- 12
- Primary Endpoint
- Change From Baseline in Pharmacodynamic Tissue Biomarkers- Protein Expression of VISTA (V-domain Ig suppressor of T cell activation)
Study Overview
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of JNJ-61610588 in participants with advanced cancer in order to determine a recommended Phase 2 dose (RP2D) for further evaluation in specific tumor types.
Detailed Description
The purpose of this study is to see if JNJ-61610588 is safe and useful for treating participants with advanced cancer. This study consists of up to 4 parts. Part 1 will determine what dose of JNJ-61610588 can be given safely to advanced cancer participants. Part 2 will look at how participants with metastatic non-small cell lung cancer respond to a safe dose of JNJ-61610588. Parts 3 and 4 will test whether the dose of JNJ-61610588 identified in Part 1 is a safe and effective therapy for participants with specific types of advanced cancers (lung, pancreas, cervical, colorectal, head and neck). Participants will receive study drug in an outpatient setting. Participants safety will be monitored throughout the study.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •The participant has a solid tumor. Parts 2 and 3 are limited to participants with non-small cell lung cancer. Part 4 is limited to participants with small cell lung, head and neck, pancreatic, colorectal, and cervical cancers
- •Tumor progression following at least one prior standard therapy
- •The participant has a radiographically measurable tumor. Evaluable disease is acceptable for Part 1 only
- •The participant is willing to consent to provide a tumor tissue sample (fresh biopsy) before (Parts 2 and 3) and after (Part 2 only) receiving the study drug
- •The participant is able to carry out daily life activities without difficulty
- •The participant does not have significant side effects from previous anti-cancer treatment
- •The participant has adequate organ and blood cell counts
- •Sexually active participants must use medically acceptable methods of contraception during the course of this study
Exclusion Criteria
- •The participant has a history of major surgery or treatment other cancer therapy within 2-6 weeks before starting the study
- •The participant has an untreated brain tumor
- •Current severe, uncontrolled systemic disease including an ongoing, active infection requiring treatment with antibiotics
- •The participant has high blood pressure or diabetes that is not well-controlled with medication
- •History of clinically significant heart problems
- •History of severe side effects toimmunotherapy
- •The participant is pregnant, breastfeeding, or planning to become pregnant or father a child
- •Positive for Hepatitis B, Hepatitis C, or HIV
- •The participant has received anticoagulant therapy with the exception of aspirin within 1 week of starting the study
Arms & Interventions
Part 1: Dose Escalation
Participants with advanced solid tumors will receive intravenous infusions of JNJ-61610588 until disease progression. Dose escalation will continue until the maximum tolerated dose is reached.
Intervention: JNJ-61610588 (Drug)
Part 2: Biomarker Evaluation
Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at or below the recommended Phase 2 dose (RP2D) until disease progression.
Intervention: JNJ-61610588 (Drug)
Part 3: Dose Expansion
Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
Intervention: JNJ-61610588 (Drug)
Part 4: Dose Expansion
Participants with advanced solid tumors will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
Intervention: JNJ-61610588 (Drug)
Outcomes
Primary Outcomes
Change From Baseline in Pharmacodynamic Tissue Biomarkers- Protein Expression of VISTA (V-domain Ig suppressor of T cell activation)
Time Frame: Approximately 2.5 years
Pre- and posttreatment tissue samples will be stained by immunohistochemistry for protein expression of VISTA.
Frequency of Dose Limiting Toxicity (DLT)
Time Frame: Approximately 2.5 years
The Dose Limiting Toxicity (DLT) is based on adverse events and includes unacceptable hematologic toxicity, unacceptable non-hematologic toxicity of Grade 3 or higher, and treatment delay greater than 2 weeks.
Change From Baseline in Pharmacodynamic Blood Biomarkers- Total Blood Cell Counts
Time Frame: Approximately 2.5 years
Standard hematology laboratory tests will be used to evaluate total blood cell counts in blood samples collected pre- and posttreatment.
Change From Baseline in Pharmacodynamic Blood Biomarkers- Markers of Monocyte Activation
Time Frame: Approximately 2.5 years
Flow cytometry will be used to evaluate markers of monocyte activation in blood samples collected pre- and posttreatment.
Change From Baseline in Pharmacodynamic Blood Biomarkers- Markers of T Cell Activation
Time Frame: Approximately 2.5 years
Flow cytometry will be used to evaluate markers of T cell activation in blood samples collected pre- and posttreatment.
Number of Participants with Adverse Events (AEs) and Serious AEs
Time Frame: Approximately 2.5 years
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Change From Baseline in Pharmacodynamic Tissue Biomarkers- Markers Associated With Immune Infiltrate Including CD3, CD4, CD8, Forkhead box P3, CD68, and PD-L1.
Time Frame: Approximately 2.5 years
Pre- and posttreatment tissue samples will be stained by immunohistochemistry for markers associated with immune infiltrate including CD3, CD4, CD8, forkhead box P3, CD68, and PD-L1.
Secondary Outcomes
- Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])(Approximately 2.5 years)
- Assessment of Anti-Tumor Activity, as Assessed by Duration of Response(Approximately 2.5 years)
- Maximum Serum Concentration (Cmax) of JNJ-61610588(Approximately 2.5 years)
- Assessment of Anti-Tumor Activity, as Assessed by the Overall Response Rate (ORR)(Approximately 2.5 years)
- Elimination Half-Life (t1/2)(Approximately 2.5 years)
- Area Under the Serum Concentration-Time Curve From t1 to t2 Time (AUC[t1-t2]) of JNJ-61610588(Approximately 2.5 years)
- Number of Participants With Anti-JNJ-61610588 Antibodies(Approximately 2.5 years)